痰嗜酸粒细胞在支气管哮喘气道炎症中作用的研究进展

Research Progress in Role of Sputum Eosinophil in Airway Inflammation in Bronchial Asthma

痰嗜酸粒细胞(EOS)作为支气管哮喘的炎症效应细胞,与哮喘患者气道炎症、气道重构密切相关,在哮喘发病机制中起重要作用。痰EOS作为评价哮喘治疗效果的重要指标,具有评价治疗反应性、预测哮喘再次发作风险以及提示预后等作用。连续动态监测痰EOS计数,有助于评估哮喘治疗的反应性和充分性,将其作为气道炎症标志物的哮喘管理模式在哮喘临床管理中具有一定的参考价值。由于不同哮喘患者存在气道炎症表型差异,明确表型并分别给予精准治疗方案,可优化哮喘治疗的管理方法。目前,抗白细胞介素-5治疗支气管哮喘已显示出一定的功效,针对哮喘气道EOS炎症靶向药物的治疗已得到肯定,靶向药物为未来哮喘的治疗提供了更多可能性。

As inflammatory effector cells of bronchial asthma,sputum eosinophil(EOS) are closely related to airway inflammation and airway remodeling in patients with asthma,and play an important role in the pathogenesis of asthma.As an important indicator to evaluate the therapeutic effect of asthma,sputum EOS have the function of evaluating the therapeutic response,predicting the risk of asthma recurrence and indicating the prognosis.Continuous and dynamic monitoring of sputum EOS count is helpful to evaluate the reactivity and adequacy of asthma treatment.The asthma management model with EOS as a marker of airway inflammation has certain reference value in the clinical management of asthma.Due to the differences in airway inflammation phenotypes among different asthma patients,clear phenotypes and precise treatment options can optimize the management of asthma treatment.At present,anti-interleukin-5 therapy has shown certain efficacy in the treatment of bronchial asthma,and drugs targeting airway EOS inflammation have been confirmed in the treatment of asthma.Targeted drugs provide more possibilities for the treatment of asthma in the future.